Iovance Biotherapeutics (IOVA) AI Stock Analysis

• Market Cap: $581.05M
• Dividend Yield: N/A
• Average Volume (3M): 11.16M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.01
• Revenue Growth: 11070.12%
• EPS Growth: 32.07%
• Country: US
• Employees: 838
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.36
• Shares Outstanding: 333,934,400
• 10 Day Avg. Volume: 10,367,018
• 30 Day Avg. Volume: 11,159,450
• PEG Ratio: -0.18
• Price to Book (P/B): 2.04
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -3.25
• Enterprise Value/Market Cap: 5.92
• Enterprise Value/Revenue: 6.87
• Enterprise Value/Gross Profit: 84.24
• Enterprise Value/Ebitda: -2.27
• 1Y Price Target: $10.00
• Price Target Upside: 471.43% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 11

• Rating: 48 Neutral
• Price Target: $2.00 ▲(14.29%Upside)

Iovance Biotherapeutics' stock score reflects its current growth phase marked by significant revenue increases and strong equity, offset by ongoing losses and cash flow challenges. The technical indicators suggest bearish momentum, while mixed earnings call sentiments and recent corporate events add moderate risk. The valuation is impacted by negative earnings, typical for a company investing heavily in growth.

Positive Factors

Clinical Efficacy

Demonstrating clinical efficacy in additional solid tumors could be key to reigniting enthusiasm with the investor community.

Efficacy and Safety

No new safety signals were observed, reinforcing AMTAGVI's favorable long-term safety profile.

Market Potential

There is significant market and value generating potential for AMTAGVI, and the positive results and KOL conversations at ASCO '25 help reaffirm that position.

Negative Factors

Competitive Landscape

The increasingly competitive landscape in advanced melanoma poses challenges for AMTAGVI, with emerging therapies aiming to raise the bar on efficacy and safety.

Implementation Challenges

The slower Amtagvi ramp was driven by implementation issues and activations of smaller authorized treatment centers, which may be hampered by insufficient hospital infrastructure, limited resources, and potential reimbursement hurdles.

Revenue and Financial Guidance

The stock has experienced negative pressure due to the lower than expected AMTAGVI revenue and downward revised financial guidance.

Iovance Biotherapeutics Business Overview & Revenue Model

Company Description

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

How the Company Makes Money

Iovance Biotherapeutics generates revenue primarily through the development and potential commercialization of its proprietary TIL therapy products. The company's revenue model is based on bringing these therapies to market either independently or through partnerships with other pharmaceutical companies. Iovance may earn income through licensing agreements, collaboration with other firms, and potential future sales of approved therapies. Additionally, significant partnerships or alliances with larger pharmaceutical companies can provide funding, milestone payments, and royalties, contributing to its revenue streams.

Iovance Biotherapeutics Financial Statement Overview

Summary

Iovance Biotherapeutics is experiencing substantial revenue growth with its recent revenue generation marking a positive trajectory. However, the company remains unprofitable with negative net income and operational inefficiencies. The strong equity position and low leverage provide some financial stability, but sustained losses and negative cash flow are significant concerns.

Income Statement

Iovance Biotherapeutics has shown substantial revenue growth with total revenue increasing significantly from $1.18 million in 2023 to $212.68 million in TTM (Trailing-Twelve-Months), marking its first substantial revenue generation. However, despite revenue growth, the company remains unprofitable with a negative net income of $375.36 million in TTM. The gross profit margin is 19.2% in TTM, reflecting that costs are still high relative to revenue. The EBIT and EBITDA margins are negative, indicating ongoing operational inefficiencies and high operating costs.

Balance Sheet

The balance sheet shows a relatively strong equity position, with a debt-to-equity ratio of 0.07, suggesting low leverage. Stockholders' equity stands at $767.87 million, indicating financial stability. However, the negative net income affects the return on equity, which remains negative. The equity ratio is 79.4%, reflecting a strong capital structure with substantial equity financing.

Cash Flow

The company has a negative operating cash flow of $334.39 million in TTM, demonstrating cash outflows from operations. Free cash flow also remains negative at $347.50 million, indicating challenges in generating cash from operations after capital expenditures. However, the firm successfully raised $340.40 million through financing activities, supporting its cash position.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	212.68M	164.07M	1.19M	0.00	0.00	0.00
Gross Profit	40.83M	40.08M	-9.57M	-21.14M	-13.98M	-8.71M
EBITDA	-354.01M	-351.67M	-427.43M	-374.76M	-328.27M	-250.87M
Net Income	-375.36M	-372.18M	-444.04M	-395.89M	-342.25M	-259.58M
Balance Sheet
Total Assets	966.74M	910.43M	780.35M	663.98M	777.33M	768.46M
Cash, Cash Equivalents and Short-Term Investments	359.71M	323.78M	279.87M	471.85M	596.00M	629.44M
Total Debt	53.72M	58.26M	75.86M	84.45M	71.53M	51.66M
Total Liabilities	198.88M	200.02M	195.74M	164.34M	155.67M	111.96M
Stockholders Equity	767.87M	710.40M	584.61M	499.64M	621.66M	656.50M
Cash Flow
Free Cash Flow	-347.50M	-364.05M	-384.11M	-313.18M	-265.51M	-251.93M
Operating Cash Flow	-334.39M	-352.98M	-361.82M	-292.76M	-227.94M	-205.13M
Investing Cash Flow	30.96M	-96.41M	-155.24M	256.45M	132.00K	-317.85M
Financing Cash Flow	340.40M	390.66M	462.96M	190.15M	239.27M	576.42M

Iovance Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.75
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IOVA, the sentiment is Negative. The current price of 1.75 is below the 20-day moving average (MA) of 1.97, below the 50-day MA of 2.27, and below the 200-day MA of 5.89, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 38.70 is Neutral, neither overbought nor oversold. The STOCH value of 17.39 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IOVA.

Iovance Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PCRX	59 Neutral	$1.08B	―	-12.27%	―	3.08%	-247.82%
ARDX	57 Neutral	$933.10M	―	-36.26%	―	127.33%	21.31%
VRDN	55 Neutral	$1.18B	―	-49.41%	―	4.86%	10.13%
Sector *	51 Neutral	$7.55B	0.30	-61.90%	2.27%	17.11%	1.58%
SNDX	48 Neutral	$758.94M	―	-93.70%	―	―	-25.83%
IOVA	48 Neutral	$581.05M	―	-51.85%	―	11070.12%	32.07%
ETNB	42 Neutral	$1.42B	―	-69.30%	―	―	-68.13%

Iovance Biotherapeutics Corporate Events

Iovance Biotherapeutics CFO Resignation Announced

On June 10, 2025, Jean-Marc Bellemin, the Chief Financial Officer of Iovance Biotherapeutics, announced his resignation effective July 10, 2025, to pursue other opportunities. This departure may impact the company’s financial leadership and strategic direction as it continues to develop cancer immunotherapies.

The most recent analyst rating on (IOVA) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.

Iovance Biotherapeutics Approves Key Proposals at Annual Meeting

On June 10, 2025, Iovance Biotherapeutics held its Annual Meeting of Stockholders virtually, where stockholders voted on five key proposals. These included the election of directors, approval of executive compensation, ratification of Ernst & Young LLP as the accounting firm, and amendments to increase shares in the equity incentive and employee stock purchase plans. All proposals were approved, reflecting strong shareholder support and potentially enhancing the company’s operational flexibility and strategic initiatives.

The most recent analyst rating on (IOVA) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Iovance Biotherapeutics stock, see the IOVA Stock Forecast page.